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Globally, carcinoma of lung is the predominant cause of cancer death 
among both men and women. While hematogenous spread from primary 
lung cancer to multiple other organs is frequently reported, metastases of 
malignant tumors to diaphragm and spleen are rare. Nowadays, Positron 
emission tomography (PET) with 18 F- fluorodeoxyglucose (FDG) has 
emerged in such a way that it has become an effective imaging technol-
ogy for the evaluation of different carcinomas, particularly for cancer 
staging and follow up after therapy. PET scan is able to provide metabolic 
information. In this case, we present an attractive unified PET/CT scan 
image in a patient with lung carcinoma having unusual diaphragm and 
splenic metastases. So, PET/CT imaging could strongly identified rare 
and unusual metastatic sites of cancer and added more appropriate staging 
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1. Introduction
Globally, carcinoma of lung is the predominant cause of cancer death among both men and women [1]. While there has been advancements in 
imaging modalities in the last twenty years, the maximum 
carcinoma of lung are still only identified due to evolve-
ment of remote metastases.  The spread of blood-borne 
metastases to numerous organs is usually identified and 
documented. The most common metastatic sites from car-
cinoma of lung are liver, adrenal glands, bone and brain [1]. 
Metastases of malignant tumors to spleen and diaphragm 
are rare [2,3]. Nowadays, Positron emission tomography 
(PET) with 18 F- fluorodeoxyglucose (FDG) has emerged 
in such a way that it has become an effective imaging 
technology for the evaluation of different carcinomas, 
particularly for cancer staging and follow up after therapy. 
PET scan is able to provide metabolic information [2]. In 
this case report, we introduce an attractive unified PET/
CT scan image in a patient with lung carcinoma having 
unusual diaphragm and splenic metastases.
2. Case Report
This 50 years-old patient was referred to Institute of Nu-
clear medical Physics, Savar for initial staging of adeno-
carcinoma in left lung (upper Zone). PET/CT scan image 
was taken 45 min after 5 mCi FDG injection (Figure 1). 
Maximum Intensity Projection (MIP) image of PET/CT 
(a), Coronal view of PET/CT fusion image (b) and cross 
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sectional image at thorasic level (c) demonstrated a 87 × 
44 mm left upper lobe mass with intense hypermetabolism 
(SUVmax 12.8). PET/CT image (d) and corresponding 
CT image (e) showed thickening (8.5 mm) of left crus 
of the diaphragm with SUVmax 13.5. Additionally, a 18 
mm subcapsular hypodense lesion on spleen with moder-
ate hypermetabolism were detected (SUVmax 6.7) (e, f). 
PET/CT imaging can identify definite metastatic lesions 
into the diaphragm and spleen (d, f).
Figure 1. Positron Emission Tomography (PET-CT) scan 
image of this Case patient
Note: MIP view of PET-CT scan (a) Coronal view of PET-CT hybrid image 
(b) and cross sectional view at thorasic level (c) demonstrated a 87 × 44 mm 
mass with intense hypermetabolism (SUVmax 12.8) in left lung upper lobe. 
PET-CT image (d, White arrow) and corresponding CT image (e, White 
arrow) showed thickening (8.5 mm) of left crus of the diaphragm with SU-
Vmax 13.5. Additionally, a 18 mm subcapsular hypodense lesion on spleen 
with moderate hypermetabolism were detected (SUVmax 6.7) in PET-CT 
image (f, white arrow) and corresponding CT image (e, red arrow). 
3. Discussion
Neither diaphragm nor splenic invasion was verified his-
tologically on a stage IV lung carcinoma patient having 
distant metastases. This is because an invasive biopsy 
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would be required.  The pattern of FDG uptake in benign 
pathologic conditions, as well as physiological variants 
and metastatic disease is clearly different without any 
histopathological diagnosis. Recognising hypermetabolic 
foci at diaphragm in patients having pulmonary pathology 
is quite significant. Bilateral high FDG uptake at the crura 
of diaphragm is usually due to hyperventilation but in this 
case FDG uptake occurs unilaterally [4]. Asymmetrical hy-
permetabolic focus which is not on the expected physio-
logical area in the upper abdomen is difficult to diagnosis 
on PET/CT image [5]. Furthermore, PET/CT fusion imag-
ing has ability to detect the benign nature of focal normal 
fatty tissue uptake.
Carcinoma of lung can be classified histopathologically 
into small cell lung carcinoma (SCLC-15% to 20%) and 
non-small cell lung carcinoma (NSCLC-80%). Adenocar-
cinoma (50% of cases), squamous cell carcinoma (40% of 
cases), large-cell carcinoma (almost 10% of cases), and 
rarely adenosquamous carcinoma are histological sub-
types of NSCLC. PET/CT is an accepted modern imaging 
technology for both mediastinal and distant staging of 
NSCLC. Presence of widespread metastatic involvement 
identifies and categorizes the patient as having stage IV 
disease. The usual metastatic sites from NSCLC are liver, 
adrenal glands, bone and brain [6]. Rarely, it has been re-
ported that NSCLC metastases are present in soft tissue, 
kidney, peritoneum, spleen, pancreas, intestine, bone mar-
row, eye, ovary, thyroid, heart, breast, nasal cavity, and 
tonsils [7]. Unusual diaphragm and splenic metastases from 
lung carcinoma were depicted in this case report. Invasion 
of malignant tumors to spleen and to diaphragm are rare-
ly observed [2,3]. Currently the documented incidence of 
splenic metastasis from primary lung cancer is 1.2–5.6%. 
Metastasis to spleen is predominantly noted in the extreme 
stage as part of a widespread metastatic disease. Generally 
at this stage 3–6 other organs are also involved as well [3].
4. Conclusion
Although the patient in this case was already at stage IV, 
PET/CT could strongly identified rare and unusual meta-
static sites of cancer and added more appropriate staging. 
PET/CT fusion image was able to find out lesions to a 
greater extent than where either PET or CT was used 
alone. Whatmore, PET-CT imaging provides excellent an-
atomic information of pathological FDG uptake.
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